Epizyme

IPO

Transformative therapies against novel epigenetic targets

Public · Cambridge, United States · Founded 2007 · $154.0M raised

Employees
201–500
Founded
2007
Business Model
B2B
Total Funding
$154.0M
Last Round
$100.0M Growth EquityNov 2019
Rounds
3
Type
Public

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 4 funding rounds and 7 investors for this company. The full record is or through the API.

About

Epizyme is a commercial-stage biopharmaceutical company creating innovative drugs for major diseases based on epigenetics discoveries. It developed therapies targeting epigenetic targets for cancer and was acquired by Ipsen.

Summary

Epizyme is a Biotech company based in Cambridge, United States, founded in 2007. It has raised $154.0M in total across 3 rounds, most recently a $100.0M Growth Equity round in Nov 2019. Investors include Royalty Pharma, Bay City Capital and MPM Capital.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding & Exit History

Growth EquityRoyalty Pharma InvestmentNov 2019
$100.0M

Sign up to see all 4 events

Funding: Series A through Growth Equity. Amounts, valuations, and investors where available.

Investors

Similar Companies

OricIPO

San Diego-based clinical stage biopharmaceutical company focused on the development of small mole...

South San Francisco, United States51–200Biotech, Healthcare
Private EquityTotal funding$647.0MFeb 2026
AsymchemIPO

Asymchem is a pharmaceutical CDMO providing R&D, chemistry, manufacturing, and control services t...

Tianjin, China5001–10000Biotech, Drug Discovery
Private EquityTotal funding$2.3BFeb 2020
Sana BiotechnologyIPO

Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...

Seattle, United States201–500Biotech, Healthcare
Series DTotal funding$1.4BJun 2020
Abogen Biosciences

Abogen Biosciences develops RNA therapeutics using integrated mRNA design, lipid nanoparticle del...

Suzhou, China201–500Biotech, Drug Discovery
Extension RoundTotal funding$1.2BNov 2021
ArsenalBio

Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...

San Francisco, United States201–500Biotech, Life Sciences
Series CTotal funding$955.0MSep 2024
Lyell ImmunopharmaIPO

Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...

South San Francisco, United States201–500Biotech, Healthcare
Venture RoundTotal funding$884.0MJul 2025

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Epizyme on Indexed.vc
<a href="https://indexed.vc/companies/epizyme"><img src="https://indexed.vc/api/badge/company/epizyme" alt="Epizyme on Indexed.vc" width="260" height="76" /></a>